User:ChrisMisu/Drug development

Article body
For example, in 2016, Pfizer's cumulative probability of success was 4%, compared with 8% for the industry. After increasing early investment in the biology of the target disease and the pharmacology of an NME, Pfizer revived their R&D pipeline and expanded its NME portfolio which enabled it to use this enhanced understanding to weed out failures early and take calculated risks to accelerate success. By 2020, Pfizer had achieved a cumulative success of 21%, versus 11% for the industry.